Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 12
2013 28
2014 29
2015 67
2016 70
2017 63
2018 66
2019 75
2020 77
2021 138
2022 105
2023 96
2024 109
2025 86
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Cited In for PMID: 22186141

961 results

Results by year

Filters applied: . Clear all
Page 1
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Woo SR, et al. Cancer Res. 2012 Feb 15;72(4):917-27. doi: 10.1158/0008-5472.CAN-11-1620. Epub 2011 Dec 20. Cancer Res. 2012. PMID: 22186141 Free PMC article.
Soluble immune checkpoints as diagnostic biomarkers in bladder cancer.
Andrzejczak A, Krajewski W, Jaskuła E, Chorbińska J, Tomkiewicz A, Sarat K, Mroczek R, Małkiewicz B, Szydełko T, Karabon L. Andrzejczak A, et al. Biomark Res. 2026 Apr 14;14(1):44. doi: 10.1186/s40364-026-00918-y. Biomark Res. 2026. PMID: 41981705 Free PMC article.
Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study.
Wang Q, Xiong A, Mao C, Wang W, Cui J, Fang J, Zhuang W, Yang K, Zuo W, Yang J, Ye L, Zhang Z, Sheng Z, Liu Z, Wang D, Du X, Yi T, Long S, Xu N, Zhou C. Wang Q, et al. Cancer Immunol Immunother. 2026 Jan 27;75(2):56. doi: 10.1007/s00262-026-04299-x. Cancer Immunol Immunother. 2026. PMID: 41591537 Free PMC article. Clinical Trial.
961 results